BioSpace News Archive

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET.

Anbio Biotechnology (“Anbio”), a leading global diagnostic device and assay company, today announced the company will showcase

via NewMediaWire – Sigyn Therapeutics, Inc., a development-stage medical technology company, disclosed that a 1-for-40 reverse split of its common stock was implemented on January 31, 2024.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.

Nevro Corp. (NYSE: NVRO) today announced the publication of a consensus statement summarizing recommendations based on outcomes from a December 2022 global, interdisciplinary panel, “Advances in the Management of Painful Diabetic Neuropathy,” at the Worldwide Initiative for Diabetes Education (WorldWIDE Diabetes) Virtual Global Summit.

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will participate in two upcoming healthcare conferences.

Gilead Sciences, Inc. announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET.

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. signed a cooperation agreement with Beijing Tong Ren Tang Group during the First Conference of Partners of Tong Ren Tang, which was held in Beijing from January 17 to 19.